- |||||||||| opipramol / Generic mfg.
Trial completion date, Trial primary completion date: Selected Disorders and Sleep Bruxism (clinicaltrials.gov) - May 7, 2024
P=N/A, N=100, Enrolling by invitation,
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| opipramol / Generic mfg.
Trial completion date, Trial primary completion date: Selected Disorders and Sleep Bruxism (clinicaltrials.gov) - Feb 8, 2023
P=N/A, N=100, Enrolling by invitation,
Due to its capacity to modulate the lipid and carbohydrate metabolisms, opipramol deserves further studies in order to explore its therapeutic potential for the treatment of obese and diabetic states. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- |||||||||| opipramol / Generic mfg.
Trial completion date, Trial primary completion date: Selected Disorders and Sleep Bruxism (clinicaltrials.gov) - Jun 1, 2022
P=N/A, N=100, Enrolling by invitation,
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- |||||||||| opipramol / Generic mfg.
Preclinical, Journal: Chronic opipramol treatment extinguishes cocaine craving through Rac1 in responders: A rat model study. (Pubmed Central) - Jan 5, 2022
We postulate that chronic activation of σ-1R, through a dynamic interaction with Rac1, may suggest a new approach to treat substance use disorder (SUD). Rac1 inhibition is a prerequisite for decreasing drug seeking and rehabilitation, and this can be achieved by opipramol, a medication that can be given during detoxification.
- |||||||||| opipramol / Generic mfg.
Trial completion date, Trial primary completion date: Selected Disorders and Sleep Bruxism (clinicaltrials.gov) - Apr 22, 2021
P=N/A, N=100, Enrolling by invitation,
This review will inform best practice in treatment and clinical research of this highly prevalent and burdensome disorder. Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||||||||| opipramol / Generic mfg.
Trial completion date, Trial primary completion date: Selected Disorders and Sleep Bruxism (clinicaltrials.gov) - Oct 20, 2020
P=N/A, N=100, Enrolling by invitation,
However, the subject requires further research on a larger population including a control group. Trial completion date: Sep 2020 --> Dec 2020 | Trial primary completion date: Sep 2020 --> Dec 2020
- |||||||||| opipramol / Generic mfg.
Trial completion date, Trial primary completion date: Selected Disorders and Sleep Bruxism (clinicaltrials.gov) - Jul 1, 2020
P=N/A, N=100, Enrolling by invitation,
These findings indicate that opipramol has a pro-convulsant effect, which is possibly mediated through activation of sigma-1 receptors. Trial completion date: May 2020 --> Sep 2020 | Trial primary completion date: May 2020 --> Sep 2020
- |||||||||| Ensidon (opipramol) / Sun Pharma, Novartis, risperidone / Generic mfg., Egis, olanzapine / Generic mfg.
Journal, Adverse events: Opipramol Inhibits Lipolysis in Human Adipocytes without Altering Glucose Uptake and Differently from Antipsychotic and Antidepressant Drugs with Adverse Effects on Body Weight Control. (Pubmed Central) - Mar 11, 2020
Opipramol did not impair insulin activation of glucose transport but inhibited monoamine oxidase (MAO) activity to the same extent as antidepressants recognized as MAO inhibitors (pargyline, harmine, or phenelzine), whereas antipsychotics were inefficient. Considering its unique properties, opipramol, which is not associated with weight gain in treated patients, is a good candidate for drug repurposing because it limits exaggerated lipolysis, prevents hydrogen peroxide release by amine oxidases in adipocytes, and is thereby of potential use to limit lipotoxicity and oxidative stress, two deleterious complications of diabetes and obesity.
- |||||||||| opipramol / Generic mfg.
Trial completion date, Trial primary completion date: Selected Disorders and Sleep Bruxism (clinicaltrials.gov) - Feb 5, 2020
P=N/A, N=100, Enrolling by invitation,
Considering its unique properties, opipramol, which is not associated with weight gain in treated patients, is a good candidate for drug repurposing because it limits exaggerated lipolysis, prevents hydrogen peroxide release by amine oxidases in adipocytes, and is thereby of potential use to limit lipotoxicity and oxidative stress, two deleterious complications of diabetes and obesity. Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Dec 2019 --> Mar 2020
- |||||||||| Clinical, Journal: Antidepressants and the risk of death in older patients with depression: A population-based cohort study. (Pubmed Central) - Jan 10, 2020
This study suggests that ADs recommended as first-line treatment in patients with depression have a similar safety profile with regard to the risk of death, especially in very old patients and in those with dementia. Further research is needed to investigate the risk of death for individual ADs in specific subgroups such as patients with cancer or cardiovascular disease.
- |||||||||| opipramol / Generic mfg.
Trial completion date, Trial primary completion date: Selected Disorders and Sleep Bruxism (clinicaltrials.gov) - Oct 11, 2019
P=N/A, N=100, Enrolling by invitation,
Our objective is to raise awareness of DIP as an adverse effect of opipramol. Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- |||||||||| opipramol / Generic mfg.
Trial primary completion date: Selected Disorders and Sleep Bruxism (clinicaltrials.gov) - Sep 25, 2018
P=N/A, N=100, Enrolling by invitation,
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial primary completion date: Jul 2018 --> Dec 2018
- |||||||||| opipramol / Generic mfg.
Trial primary completion date: Selected Disorders and Sleep Bruxism (clinicaltrials.gov) - Apr 17, 2018
P=N/A, N=100, Enrolling by invitation,
Trial primary completion date: Jul 2018 --> Dec 2018 Trial primary completion date: Mar 2018 --> Jul 2018
- |||||||||| Enrollment change, Trial termination, Trial primary completion date, Adverse events: Pharmacovigilance in Gerontopsychiatric Patients (clinicaltrials.gov) - Oct 19, 2017
P3, N=407, Terminated,
Trial primary completion date: Mar 2018 --> Jul 2018 N=2000 --> 407 | Recruiting --> Terminated | Trial primary completion date: Feb 2017 --> Jun 2017
- |||||||||| opipramol / Generic mfg.
Enrollment open: Selected Disorders and Sleep Bruxism (clinicaltrials.gov) - May 10, 2017
P=N/A, N=100, Enrolling by invitation,
N=2000 --> 407 | Recruiting --> Terminated | Trial primary completion date: Feb 2017 --> Jun 2017 Not yet recruiting --> Enrolling by invitation
|
